Leadership Overview
RemeGen has 5 executives leading key functions including corporate strategy, financial management, market expansion, and operational quality.
Focused on advancing biopharmaceutical innovation, RemeGen delivers life-saving treatments for autoimmune diseases and cancers while maintaining a global commitment to patient health through rigorous scientific research and development.
Focused on advancing biopharmaceutical innovation, RemeGen delivers life-saving treatments for autoimmune diseases and cancers while maintaining a global commitment to patient health through rigorous scientific research and development.
Leadership Roles at RemeGen
Jianmin Fang - Chief Executive Officer
Jianmin Fang, the Chief Executive Officer at RemeGen, directs the overarching corporate strategy and scientific vision for the organization. Overseeing the development of innovative biopharmaceuticals, the Chief Executive Officer ensures that the research pipeline remains aligned with global medical needs for autoimmune conditions and oncology. Jianmin Fang architects the long-term growth trajectory by fostering partnerships with international research institutions and clinical networks. This leadership role involves constant evaluation of drug efficacy data to maintain high standards across all therapeutic programs. By prioritizing the advancement of dual-target fusion proteins and antibody-drug conjugates, the Chief Executive Officer drives the company toward market leadership. Through rigorous oversight of the research and development lifecycle, Fang secures the competitive positioning of the firm within the global biopharmaceutical landscape, ultimately ensuring that scientific breakthroughs translate into tangible patient outcomes across diverse international markets.
Jian Lin - Executive Director & Chief Executive Officer
Jian Lin, the Executive Director & Chief Executive Officer at RemeGen, manages the governance framework and high-level administrative operations of the company. Coordinating with the Board of Directors, the Executive Director & Chief Executive Officer executes corporate policies that support the rapid scaling of drug manufacturing capabilities. Jian Lin monitors the integration of internal business units to ensure seamless collaboration between research, clinical trials, and commercialization teams. This leadership role requires balancing fiscal responsibility with the aggressive pursuit of new therapeutic indications for flagship products like Telitacicept. By streamlining organizational processes, the Executive Director & Chief Executive Officer optimizes resource allocation across the entire enterprise. Through consistent engagement with stakeholders and regulatory bodies, Lin maintains the operational integrity of the firm, facilitating sustainable growth and reinforcing the company's reputation as a premier developer of advanced medical solutions on a global scale.
Shaojing Tong - Chief Financial Officer
Shaojing Tong, the Chief Financial Officer at RemeGen, oversees the financial health and capital allocation strategies necessary to sustain intensive biopharmaceutical research. Managing the budgetary requirements for clinical trials and drug development, the Chief Financial Officer ensures that the company maintains the liquidity needed for long-term innovation. Shaojing Tong directs investor relations and financial reporting, providing transparency regarding the commercial performance of products like Disitamab Vedotin. This leadership role involves assessing the financial risks associated with global market expansion and regulatory compliance. By implementing robust fiscal controls, the Chief Financial Officer supports the strategic objectives of the executive team. Through meticulous planning and capital management, Tong secures the financial stability required to advance the company's extensive product pipeline, ultimately enabling the firm to continue delivering high-impact medical treatments to patients worldwide while maximizing value for all stakeholders involved in the enterprise.
Kaisheng Huang - Chief Operating Officer & Chief Quality Officer
Kaisheng Huang, the Chief Operating Officer & Chief Quality Officer at RemeGen, manages the end-to-end manufacturing processes and quality assurance protocols for all pharmaceutical products. Overseeing the production facilities, the Chief Operating Officer & Chief Quality Officer ensures that every drug meets stringent international safety and efficacy standards. Kaisheng Huang architects the supply chain logistics required to distribute complex fusion proteins and antibody-drug conjugates to global markets. This leadership role involves implementing advanced manufacturing technologies to improve production efficiency and consistency. By maintaining rigorous quality control systems, the Chief Operating Officer & Chief Quality Officer mitigates operational risks and ensures compliance with global regulatory requirements. Through continuous process improvement and infrastructure development, Huang supports the company's ability to scale production in response to rising demand, ultimately guaranteeing that the firm delivers high-quality, reliable medical treatments to patients across all operational regions.
Xiaoming Yang - Chief Marketing Officer
Xiaoming Yang, the Chief Marketing Officer at RemeGen, leads the commercialization strategy and market positioning for the company's portfolio of autoimmune and oncology drugs. Overseeing the launch of new therapeutic products, the Chief Marketing Officer ensures that medical professionals and healthcare systems understand the clinical benefits of the firm's antibody-drug conjugates. Xiaoming Yang architects comprehensive outreach programs that drive adoption across diverse regional markets. This leadership role involves analyzing market trends and competitive dynamics to refine the value proposition of flagship treatments. By aligning marketing initiatives with clinical data, the Chief Marketing Officer facilitates the successful integration of new drugs into standard treatment protocols. Through strategic communication and brand management, Yang expands the reach of the company's medical solutions, ensuring that patients gain access to innovative therapies while simultaneously driving revenue growth and strengthening the firm's presence in the global biopharmaceutical sector.
Explore Leadership Teams in Manufacturing
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes and enhance quality of life. Guided by a long-standing commitment to scientific research and medical advancement, the company focuses on addressing some of the world’s most significant health challenges through breakthrough therapies and healthcare solutions.
Company Leadership TW
JS
TD
Founded in 1951, Cadila Pharmaceuticals is a privately held pharmaceutical company in India. The company's integrated operations cover the entire gamut from manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products, and pharmaceutical Machinery.
Company Leadership SB
SG
Tilray was established in 2018 in British Columbia, Canada. They specialize in the research, cultivation, production and distribution of medical cannabis and cannabinoids.
Company Leadership
CM
LB
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CC
BS
SR
Frequently Asked Questions Regarding RemeGen Top Executives and Leadership Team
